ISALXIX – Munich, March 16 – 19, 2025

S U N D A Y, March 16, 2025

EDUCATIONAL SYMPOSIUM of the AGIHO
(supported by GILEAD Sciences GmbH)

10.00-11.00 Interdisciplinary Educational Symposium
Arbeitsgemeinschaft Infektionen der DGHO (AGIHO)
(Infectious Diseases Working Party of the DGHO)
Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
M. von Bergwelt, Munich, DE
Ch. Rieger, Munich, DE

10.00-10.20 O.A. Cornely, Cologne, DE
Update Antifungal Therapy

10.20-10.40 N. Giesen, Stuttgart, DE
Viral Infections of the Respiratory Tract in Hem-Onc Patients

10.40-11.00 Ch. Rieger, Munich, DE
Vaccination Strategies in Hemato-Oncology – Update of the
AGIHO Guideline

11.00-12.00 COFFEE BREAK

 

MAIN PROGRAM – ISALXIX – Munich, March 16 – 19, 2025

12.00-12.15 ISALXIX OPENING SESSION
WELCOME ADDRESS
W. Hiddemann, Munich, DE
Symposium Chairman
Lecture Hall III (Overflow Rooms: LHs IV+V)

12.15-13.55 MS I: Basic Biology of Acute Leukemias I
Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
M. Andreeff, Houston, TX, USA
I. Jeremias, Munich, DE

12.15-12.35 A. Trumpp, Heidelberg, DE
Leukemic Stem Cells: Novel Insights and Challenges into
Therapy Response and Resistance

12.35-12.55 E. Papapetrou, New York, NY, USA
Modeling Clonal Evolution to AML

12.55-13.15 G. Huls, Groningen, NL
CHIP in AML – Theoretical and Practical Considerations

13.15-13.35 Th. Oellerich, Frankfurt, DE
Proteogenomics of AML

13.35-13.55 M. „Ken“ Figueroa, Coral Gables, FL, USA
Age-Related Epigenetic Changes Contributing to
Leukemogenesis?

14.30-16.10 MS II: Basic Biology of Acute Leukemias II
Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
K. Metzeler, Leipzig, DE
K. Spiekermann, Munich, DE

14.30-14.50 E. Mansell, Rotterdam, NL
Mitochondrial Metabolism as a Druggable Driver of Hematopoietic
Stem Cell Fate in Ageing and Disease

14.50-15:10 H. Uckelmann, Frankfurt, DE
NPM1-Regulated Oncogenic Transcription

15:10-15.30 S. Rutella, Nottingham, UK
Immune Dysfunction in Subtypes of AML

15.30-15.50 P. Vyas, Oxford, UK
Premalignant CH Clones Mediate Inflammation and Progress
towards Leukemia

15.50-16:10 C. Müller-Tidow, Heidelberg, DE
Epitranscriptomics of AML

M O N D A Y, March 17, 2025

08:30-09:30 THOMAS-BÜCHNER LECTURE
Lecture Hall III (Overflow Rooms: LHs IV+V)

Introduction
C. DiNardo, Houston, TX, USA

A. Wei, Melbourne, VIC, AUS
New Treatments and Challenges in AML

09:30-10:00 COFFEE BREAK

10:00-11.40 MS III: Novel Markers for Diagnosis and Prognosis in AML
Lecture Hall III (Overflow Rooms: LHs IV+V)

Co-Chairs:
P. Valk, Rotterdam, NL
T. Herold, Munich, DE

10:00-10:20 C. Lachowiez, Portland, OR, USA
The Impact of AML Differentiation State and Genotype on
Therapeutic Decision-Making in AML

10:20-10:40 D. Heckl, Frankfurt, DE
Epigenetics in AML: Novel Therapeutic Strategies

10:40-11:00 A. Wierzbowska, Lodz, PL
Progression of CCUS to MDS/AML

11:00-11:20 K. Metzeler, Leipzig, DE
Clonal Hematopoesis during CART Cell Therapy

11:20-11:40 L. Shlush, Rehovot, IL
Targeting SRSF2 Mutations in AML

11:45-14:00 LUNCH BREAK

14:00-15:40 MS IV: Novel Approaches and Targeted Therapies
in AML I
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
B. Löwenberg, Rotterdam, NL
H. Serve, Frankfurt, DE

14:00-14:20 R. Majeti, Stanford, USA
Targeting Stem Cells in Human AML

14:20-14:40 C. DiNardo, Houston, TX, USA
Integrating Novel Therapies into Frontline AML Therapy

14:40-15:00 J. Tyner, Portland, OR, USA
Personalizing Novel Therapeutic Strategies in AML

15:00-15:20 J.E. Sarry, Toulouse, F
Targeting Metabolic Dependencies to Circumvent
Therapy Resistance in AML

15:20-15:40 A. Letai, Boston, MA, USA
Therarpeutically Applicable Gene Expression in AML

15:40-16:00 COFFEE BREAK

16:00-18:00 MS V: ON-SITE Poster Viewing and Discussion Session

Posters will be presented on the Upper Floor of the symposium venue (Floorplan Level 2).

Use this forum for stimulating discussions on a great variety of the most current topics in the field of Acute Leukemias and get a deeper insight into various subject areas.

As always, a great variety of cheese specialties and a glass of wine will be offered during the session.

All poster presenters are expected to participate in MS V to allow all participants and members of the Poster Award Committee to talk to the presenters and have a personal scientific exchange about their poster(s).

T U E S D A Y, March 18, 2025

08:30-10:10 MS VI: Novel Approaches and Targeted Therapy in AML II
Lecture Hall III (Overflow Rooms IV+V)

Co-Chairs:
R. Stone, Boston, MA, USA
K. Götze, Munich, DE

08:30-08:50 F. Perner, Hannover, DE
Menin Inhibition in AML

08:50-09:10 D. Pollyea, Aurora,USA CO, USA
Overcoming Venetoclax Resistance in AML

09:10-09:30 P. Krishnamurthy, London, UK
Macrophage (CD47/SiRPa) and NK-Cell Based
Therapies in AML

09:30-09:50 M. Andreeff, Houston, TX, USA
Epichaperone Inhibition in p53 Mutated AML

09:50-10:10 P. Montesinos, Valencia, E
FLT3 Inhibitors in Mutated and Wild-Type AML

10:30-12:30 MS VII: Current Therapeutic Strategies in AML and APL
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
A. Wierzbowska, Lodz, PL
F. Thol, Hannover, DE

10:30-10:50 S. Luger, Philadelphia, PA, USA
New Clinical Paradigm for AML in the National Clinical Trials

10:50-11:10 H. Döhner, Ulm, DE
Prognostication in Unfit AML and International Consortium Trials

11:10-11:30 Ch. Recher, Toulouse, F
Treatment Strategies and Trials in France: French AML
Intergroup Protocols

11:30-11:50 Ch. Röllig, Dresden, DE
Lessons Learned and Future Perspectives in AML Treatment:
SAL and AMLCG Algorithm and Protocols

11:50-12:10 Ch. Craddock, Birmingham, UK
Post-transplant Maintenance: For Whom, When, and How Long?

12:10-12:30 M.T. Voso, Rome, I
How we Should Treat APL

12.30-14.00 L U N C H B R E A K

14:00-15:40 MS VIII: MRD in Acute Leukemias
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
F. Ravandi, Houston, TX, USA
M. Brüggemann, Kiel, DE

14:00-14:20 Ch. Hourigan, Bethesda, MA, USA
NGS-Based MRD Testing in AML

14:20-14:40 S. Freeman, Birmingham, UK
Why and How we Should Use Preferentially Flow-Based
MRD in AML

14:40-15:00 G.J. Roboz, New York, NY, USA
Chasing MRD in AML: Does Giving Maintenance Mean
Giving Up on Cure?

15:00-15:20 R. Dillon, London, UK
Pre-Emptive Treatment of MRD Failure in AML

15:20-15:40 G. Bug, Frankfurt, DE
Is Detection of Measurable Disease Prior to Allogeneic
HCT of Clinical Relevance?

15:40-16:15 COFFEE BREAK

16:15-17:20 MS IX: Festive Award Ceremony and Presentations
Lecture Hall VI
Co-Chairs:
M. von Bergwelt, Munich, DE
F. Bassermann, Munich, DE

16:15-16:20 Poster Prize Announcement and Presentation of Certificates:
Official Announcement and Presentation of Certificates of the
2 ISALXIX Poster Prize Winners

16.20-16.30 3 Best of Free Contributions: Announcement of Award
Winners, Presentation of Certificates and Talks:
Official Announcement of this Year’s 3 Best of Free
Contributions’ Winners followed by a 10 Minutes’ Presentation

16.30-16.40 P055. Dissecting Minimal Residual Disease in Npm1-Mutated Acute Myeloid Leukemia by Transcript Quantification and Highly Multiplexed Microscopy
J.C. Schroeder et al., Tübingen, DE

16.40-16.50 P034. CSF1R Targeting T CELL Engaging Bispecific Antibodies Enables Safe and Efficient Immunotherapies in Acute Myeloid Leukemia
A. Gottschlich et al., Munich, DE

16.50-17:00 P078. Ecological Dynamics of a Community of Stem Cell Subpopulations Drive Relapses in Acute Myeloid Leukemia
E. Boët and J.-E. Sarry, Geneve, CH

17:00-17:05 Leukemia Clinical Research Award 2025 (LCRA):
Official Announcement of the LCRA 2025 Laureate followed by a
15 Minutes’ Presentation.

17:05-17:20 LCRA 2025 Laureate Talk

W E D N E S D A Y, March 19, 2025

08:30-10:10 MS X: Immunotherapy for Acute Leukemias
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
M. Manz, Zurich, CH
C. Lengerke, Tübingen, DE

08:30-08:50 L. Jeker, Basel, CH
Molecular Cell Shielding as a New Approach to
Treat Leukemia

08:50-09:10 S. Haubner, New York, NY , USA
Cooperative CAR targeting in AML

09:10-09:30 H. Poeck, Regensburg, DE
Modulation of GvL and CART Responses

09:30-09:50 M. Subklewe, Munich, DE
Antibody Based AML Immunotherapy

09:50-10:10 N. Daver, Houston, TX, USA
Triplets Including Immunotherapy Approaches

10:10-10:40 COFFEE BREAK

10:40-12:50 MS XI: Biology and Treatment Strategies of ALL
Lecture Hall III (Overflow Rooms LHs IV+V)

Co-Chairs:
H. Dombret, Paris, F
M. Stelljes, Münster, DE

10:40-11:00 C. Baldus, Kiel, DE
Integrating Complex Molecular Diagnostics into Treatment Decision Making in ALL

11:00-11:20 N. Gökbuget, Frankfurt, DE
GMALL Concepts for ALL Therapy

11:20-11:40 W. Stock, Chicago, IL, USA
Young Adults with ALL: How Can We Further Improve
Outcomes?

11:40-12:00 S. Chiaretti, Rome, I
Chemotherapy-Free Treatment of Philadelphia Chromosome-
Positive ALL?

12:00-12:20 N. Boissel, Paris, F
Novel Approaches to Treatment of T-ALL

12:20-12:40 B. Shah, Tampa, FL, USA
Mechanisms of Resistance to CAR T-Cell Therapy in
ALL/Antigen Modulation

12:40-12:50 CLOSING REMARKS